Skip to main content

Generate Biomedicines, Inc.

GENB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002100782

In the last 90 days, Generate Biomedicines, Inc. insiders filed 0 open-market purchases and 1 sale; 86 institutions reported holding it in 13F filings for Q2 2026, worth $1.69B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Generate Biomedicines, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $16.0K in total
Insiders trading
1
Net value
−$16.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Generate Biomedicines, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Generate Biomedicines, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Arnold FrancesDirector231,472Sep 3, 20262
Nally MichaelChief Executive Officer572,707Mar 6, 20262
Afeyan NoubarDirector, 10% Owner1,562,500IndirectMar 2, 20262
Flagship Pioneering, LLC10% Owner1,562,500IndirectMar 2, 20261
Flagship Pioneering Fund VI General Partner LLC10% Owner1,562,500IndirectMar 2, 20261
Nutritional Health LTP Fund General Partner LLC10% Owner1,562,500IndirectMar 2, 20261
Flagship Pioneering Fund VII General Partner LLC10% Owner1,562,500IndirectMar 2, 20261
Flagship Pioneering Special Opportunities Fund II General Partner LLC10% Owner1,562,500IndirectMar 2, 20261
FPN General Partner LLC10% Owner1,562,500IndirectMar 2, 20261
Flagship VentureLabs VI Manager LLC10% Owner1,562,500IndirectMar 2, 20261
Flagship Pioneering Fund VI, L.P.10% Owner1,562,500IndirectMar 2, 20261
Flagship VentureLabs VI LLC10% Owner1,562,500IndirectMar 2, 20261
Flagship Pioneering Special Opportunities Fund II, L.P.10% Owner1,562,500IndirectMar 2, 20261
Nutritional Health LTP Fund, L.P.10% Owner1,562,500IndirectMar 2, 20261
Flagship Pioneering Fund VII, L.P.10% Owner1,562,500IndirectMar 2, 20261
FPN II, L.P.10% Owner1,562,500IndirectMar 2, 20261
Fanucci MarshaDirector–Mar 2, 20261
Simonian Nancy ADirector–Mar 2, 20261
Bancel StephaneDirector724,160IndirectMar 2, 20261
Martin SeanChief Legal Officer & GC–Mar 2, 20261
Mendillo Jane LDirector1,500Mar 2, 20261
Vessey RupertDirector–Mar 2, 20261
Parker Paul GrayDirector–Mar 2, 20261
Grigoryan GevorgChief Technology Officer–Mar 2, 20261
Silvers JasonPresident & CFO1,000IndirectMar 2, 20261
Grous BethChief People Officer300IndirectMar 2, 20261
Lee Laurie AnneChief Medical Officer–Mar 2, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 3, 2026 (view filing)4:05 PM ETSep 12 daysArnold FrancesDirectorSSale−1.00K$16.00−$16.0K−0.4%231.5K after10b5-1
Mar 6, 2026 (view filing)Mar 42 daysNally MichaelChief Executive OfficerPPurchase+20.0K$12.00+$240.0K+3.6%572.7K after
Mar 2, 2026 (view filing)5:52 PM ETMar 2Same dayAfeyan Noubar and 7 othersDirector, 10% OwnerPPurchase+4.69M$16.00+$75.0MNew position1.56M after3 lotsDuplicate filing
Mar 2, 2026 (view filing)5:42 PM ETMar 2Same dayAfeyan Noubar and 6 othersDirector, 10% OwnerPPurchase+4.69M$16.00+$75.0MNew position1.56M after3 lots
Mar 2, 2026 (view filing)Mar 2Same dayGrous BethChief People OfficerPPurchase+300$16.00+$4.80KNew position300 after
Mar 2, 2026 (view filing)Mar 2Same daySilvers JasonPresident & CFOPPurchase+2.00K$16.00+$32.0KNew position1.00K after3 lots
Mar 2, 2026 (view filing)Mar 2Same dayMendillo Jane LDirectorPPurchase+1.50K$16.00+$24.0KNew position1.50K after